Health ConditionsBenign prostatic hyperplasia (BPH) refers to the nonmalignant growth or hyperplasia of prostate tissue and is a common cause of lower urinary tract symptoms (LUTS) in older men. The concern addressed in natural-health contexts as "prostate size and urinary flow support" relates directly to the same physiological territory: the effects of an enlarging prostate gland on the dynamics of urine storage and voiding.
BPH is defined by the American Urological Association (AUA) as a histologic diagnosis referring to the proliferation of smooth muscle and epithelial cells within the prostatic transition zone. The prostatic transition zone makes up about 5% of the prostate and is the portion that surrounds the proximal urethra. This zone is the site of continual growth throughout life.
BPH is characterised by a benign overgrowth of prostatic tissue around the urethra which ultimately constricts the urethral opening, resulting in lower urinary tract symptoms (LUTS). Symptoms associated with LUTS include urgency, frequency, nocturia, incomplete urination, and weak urinary stream.
The enlarged gland contributes to lower urinary tract symptoms through two routes: by direct bladder outlet obstruction (BOO) from enlarged tissue (the static component) and by increased smooth muscle tone and resistance (the dynamic component). The overactivity of the detrusor muscle is also thought to be a contributor to the storage symptoms seen in lower urinary tract symptoms.
Clinical BPH is one of the most common diseases in ageing men and the most common cause of lower urinary tract symptoms (LUTS). The prevalence of BPH increases after the age of 40 years, with a prevalence of 8%–60% at age 90 years. The histological prevalence of BPH at autopsy is as high as 50% to 60% for males in their 60s, increasing to 80% to 90% of those older than 70 years of age.
Up to 15% to 25% of men aged 50–65 years have lower urinary tract symptoms (LUTS) consisting of nocturia, urgency, frequency, a sensation of not completely emptying the bladder, stop-start urination, straining to urinate, a need to urinate soon after voiding, and weak urinary stream.
Some data have suggested that there is decreased risk among Asians compared to the western white population. Genetics, diet, and lifestyle may play a role here.
The condition involves a complex interplay of several anatomical and physiological systems:
The pathophysiology of male LUTS is highly complex and multifactorial, and the importance of causal factors including changes in the bladder and prostate as well as in related structures such as the pelvic vasculature and innervation has been highlighted.
Several risk factors for the development of benign prostate enlargement/hyperplasia (BPE/BPH) have been identified, including age, genetics, hormones, growth factors, inflammation, and lifestyle factors. Age is the most consistently identified non-modifiable risk factor. The incidence has been estimated to increase from 40% among males between the ages of 50 and 60 years to 90% among males older than 80 years of age.
Testosterone and dihydrotestosterone, while necessary for BPH to occur, are not the sole causes of the condition. The conversion of testosterone to DHT via 5α-reductase in prostatic tissue is a key mechanistic contributor recognized across the literature.
In recent decades there has been an increasing body of evidence evoking a strong relationship between metabolic syndrome and the development of LUTS/BPH. This relationship suggests that metabolic syndrome might be responsible not only for putting patients at higher risk of developing LUTS/BPH but also for influencing the response and outcome of therapy. A systematic review and meta-analysis observed a strong relationship between metabolic syndrome and prostatic enlargement, underlining the exacerbating role of this syndrome in inducing the development of benign prostate enlargement, as obese, dyslipidaemic and aged men have a higher risk of metabolic syndrome being a determinant factor of their prostate enlargement.
Men with metabolic syndrome have a higher prostate growth rate and larger prostate volumes than men without metabolic syndrome. Similarly, poor glycemic control has been linked to prostate enlargement.
Insulin can bind to the insulin-like growth factor receptor in prostate cells, leading to activation of the receptor and the induction of prostate cell growth and proliferation. A study on community-dwelling men in Massachusetts found that men with type 2 diabetes were 50% more likely to have clinical BPH (diagnosed by a physician or treated with surgery), even after accounting for weight. The size of the prostate is related to the prevalence of LUTS and BPH surgery, and many studies have found that diabetes was significantly associated with increased prostate volume.
Over the last decade, increased modifiable risk factors, such as metabolic disease and obesity, have resulted in an increased incidence of BPH. Inflammatory pathways represent an active area of research. Although non-modifiable risk factors — including age, genetics and geography — play significant roles in the etiology of BPH and BOO, recent data have revealed modifiable risk factors that present new opportunities for treatment and prevention, including sex steroid hormones, the metabolic syndrome and cardiovascular disease, obesity, diabetes, diet, physical activity and inflammation.
Non-modifiable risk factors, including age, genetics and geography, play significant roles in the etiology of BPH and BOO. Ethnic and geographic variation in prevalence has been documented, with population data pointing toward dietary and lifestyle differences as partial explanatory factors.
The use of some complementary health approaches such as phytotherapy for the treatment of lower urinary tract symptoms is common. Although there is limited evidence that some phytotherapeutic agents may help improve symptoms related to BPH over the short term, most of the trials conducted have been small in size, of short duration, and used varied doses and preparations.
Traditional Use: Saw palmetto (Serenoa repens) is a small palm tree native to the southeastern United States. Currently, saw palmetto is used as a dietary supplement for urinary symptoms associated with benign prostatic hyperplasia (BPH), as well as for chronic pelvic pain, decreased sex drive, migraine, hair loss, and other conditions. Saw palmetto is considered first-line therapy for BPH in several Western European countries.
Scientific Evidence: A 2023 review of 27 studies on saw palmetto in men with BPH found that this herb, when administered alone, provides little or no benefit for BPH symptoms. Definite conclusions could not be reached about the effects of combinations of herbs that include saw palmetto. Two clinical trials funded by the National Institutes of Health, both of which evaluated saw palmetto alone, were included in this review. One tested a standard dose of saw palmetto; the other tested increasing doses of saw palmetto, up to three times the usual dose. In both studies, saw palmetto did not improve BPH symptoms.
A 2012 Cochrane review of 32 randomized controlled trials involving 5,666 men with BPH found that Serenoa repens, at 2 and 3 times the usual dose, provides no improvement in urinary flow measures or prostate size in men with lower urinary tract symptoms consistent with BPH.
Because it had been suggested that saw palmetto products prepared using hexane extraction might be more effective than those prepared in other ways, the reviewers analyzed studies of these products and studies of other products separately — no difference was found in the effects of the two kinds of products on BPH symptoms.
Some combination data are more nuanced. A 2014 randomized trial of 225 men with lower urinary tract symptoms and BPH examined the efficacy and tolerability of combination therapy between saw palmetto, lycopene, and selenium plus tamsulosin versus single therapies. The findings suggest that a combination therapy of saw palmetto, lycopene, selenium, and tamsulosin is more effective than single therapies in improving International Prostate Symptom Score and increasing maximum urinary flow rate. After 6 months of treatment, the combination therapy significantly improved symptom scores compared with single therapy, and from 6 to 12 months, combination therapy demonstrated significant improvement in urine flow rate compared to tamsulosin alone.
Evidence strength: Overall, current evidence from high-quality trials and systematic reviews does not support saw palmetto monotherapy for BPH symptoms. Combination therapy data are preliminary and require further independent replication.
Traditional Use: Prunus africana (Pygeum africanum), derived from the bark of the African plum tree, is used in traditional African medicine to alleviate urinary symptoms associated with BPH.
Scientific Evidence: A 2002 Cochrane review of 18 randomized controlled trials involving 1,562 men with BPH concluded that a standardized preparation of Pygeum africanum may be a useful treatment option for men with lower urinary symptoms consistent with BPH. However, the studies included in the review were small in size, were of short duration, and used varied doses and preparations of the extract. Clinical studies have concluded that Pygeum africanum is generally well-tolerated with mild adverse effects such as diarrhea, nausea, constipation, and headache.
The bioactive compounds, including phytosterols, triterpenes and ferulic acid esters, exhibit anti-inflammatory and anti-androgenic properties that may reduce prostate enlargement and improve urinary flow dynamics. Clinical studies have demonstrated the efficacy of Pygeum extracts in reducing nocturia, improving the quality of life of patients and reducing International Prostate Symptom Score (IPSS).
Evidence strength: Preliminary to moderate. Cochrane-level review data are positive but originate from older, short-duration, heterogeneous trials. Larger, more rigorous long-term trials are lacking.
Traditional Use: Beta-sitosterol is a plant sterol found widely in nuts, seeds, and plant-derived foods, as well as concentrated in several traditional botanical medicines including Pygeum africanum and saw palmetto. It has a long history of use in European herbal medicine for urinary complaints.
Scientific Evidence: Beta-sitosterol recipients experienced improvements in peak urine flow rate and residual urinary volume in earlier clinical trials. These results were corroborated in a later study of similar design but which employed a higher dose of beta-sitosterol (130 mg daily); men who took beta-sitosterol not only experienced improvements in standardized prostate/urinary symptom assessments over placebo, but also in quality of life.
A Cochrane-level synthesis of beta-sitosterol found supportive but limited data. Data comparing men treated with beta-sitosterol to those receiving placebo indicated a significant decrease in symptom scores in the beta-sitosterol group after three and six months of treatment. In a follow-up study, these improvements were maintained for an additional 18 months of observation.
Evidence strength: Modest positive signal in a small number of randomized trials. Preparations and dosing vary substantially across studies, and long-term data are limited.
Traditional Use: Urtica dioica, also known as stinging nettle root, is well-established in herbal medicine. It has been used for centuries in European and Middle Eastern traditional medicine for conditions involving urinary difficulty and prostate discomfort.
Scientific Evidence: There is some limited evidence that Urtica dioica may be efficacious for lower urinary tract symptoms associated with BPH. A 2005 double-blind, placebo-controlled, randomized trial of Urtica dioica for treatment of BPH in 620 patients found significant improvement in International Prostate Symptom Score (IPSS), maximum urinary flow rate, and relief of lower urinary tract symptoms compared with placebo, over 6 months of treatment.
Nettle causes anti-inflammatory, anti-tumor, antiviral effects and modulation of the immune system, and relieves the symptoms of benign prostatic hyperplasia due to the compounds it contains, such as phytosterols, lignans and polysaccharides. In a clinical trial, 287 BPH patients who had been treated with nettle (Urtica dioica) showed significant reduction in IPSS, serum PSA and prostate size.
Urtica dioica produces a lectin which binds to human sex hormone-binding globulin (SHBG), which is one proposed mechanism of action.
Evidence strength: Limited but suggestive positive signal, primarily from single trials or combination studies. Well-designed replication studies are needed.
Traditional Use: The pharmacologic use of plants and herbs (phytotherapy) for the treatment of LUTS associated with BPH has been growing steadily. Cernilton, prepared from the rye-grass pollen Secale cereale, is one of several phytotherapeutic agents available for the treatment of BPH.
Scientific Evidence: Based on early toxicologic and clinical studies, in 1994, Commission E approved the use of S. cereale, P. pratense, and Z. mays pollen extract for treatment of micturition difficulties associated with Alken stage I–II benign prostate enlargement.
A 2002 Cochrane Systematic Review of rye grass pollen for BPH found human trials to be limited by short duration, limited number of enrollees, gaps in reported outcomes, and unknown quality of the preparations utilized. However, the authors concluded that the available evidence suggests rye grass pollen is well-tolerated and modestly improves urologic symptoms including nocturia. Additional randomized controlled trials were deemed necessary to evaluate long-term clinical effectiveness and safety of rye grass pollen.
In the systematic review, 444 men were enrolled in two placebo-controlled and two comparative trials lasting 12–24 weeks. Some clinical studies have documented that rye grass pollen (Cernilton) improves self-rated urinary symptoms but does not improve urinary flow rates. Even if the overall studies carried out suggest that rye grass pollen modestly improves urological symptoms, Wilt et al., in 2011, withdrew an update to the 2000 Cochrane review citing lack of adequate information to make a significant update.
Evidence strength: Weak to preliminary. Commission E approval exists, and some trial data show modest symptomatic improvement, but trials are few, heterogeneous, and of short duration. No confirmed effect on objective urine flow parameters.
Traditional Use: Pumpkin seed has been used in traditional Central European (particularly German and Eastern European) folk medicine for urinary complaints and prostate discomfort for centuries, and the German Commission E lists it for irritable bladder and micturition problems.
Scientific Evidence: The safety and efficacy of a proprietary pumpkin seed soft extract (PSE) were investigated in two randomized placebo-controlled 12-month studies (the Bach and GRANU studies). Both trials studied LUTS/BPH patients with an International Prostate Symptom Score (IPSS) ≥13 points at baseline. The Bach study demonstrated positive effects of PSE compared to placebo, but no difference between treatments was observed in the GRANU study.
Pumpkin (Cucurbita pepo) seed oil relieved BPH symptoms with no side effects, but was not as effective as tamsulosin. Further studies are required to confirm the role of pumpkin seed oil as an option for the treatment of BPH symptoms.
Preclinical evidence indicates plausible mechanisms: in a rat model, oral pumpkin seed oil given alongside testosterone for 20 days inhibited testosterone-induced increases in prostate size ratio, with stronger effects at higher doses. Another rat study isolated phytosterols from pumpkin seed oil and administered them directly to the stomach for four weeks; this reduced pathological prostate enlargement and suppressed expression of 5-alpha reductase and androgen-pathway markers, while shifting signaling toward less proliferation and more apoptosis.
Evidence strength: Mixed. Preclinical data are supportive. Human trial results are inconsistent. Evidence strength is preliminary.
Traditional Use: Lycopene is not associated with a specific traditional medicinal tradition but is a dietary carotenoid consumed widely through tomatoes and tomato-based products across multiple cultures.
Scientific Evidence: Lycopene is a phytochemical that belongs to a group of pigments known as carotenoids. It is red, lipophilic, and naturally occurring in many fruits and vegetables, with tomatoes and tomato-based products containing the highest concentrations of bioavailable lycopene. Several epidemiological studies have linked increased lycopene consumption with decreased prostate cancer risk.
These findings are supported by in vitro and in vivo experiments showing that lycopene not only enhances the antioxidant response of prostate cells, but is able to inhibit proliferation, induce apoptosis and decrease the metastatic capacity of prostate cancer cells. However, there is still no clearly proven clinical evidence supporting the use of lycopene in the prevention or treatment of prostate cancer, due to the only limited number of published randomized clinical trials and the varying quality of existing studies.
In the BPH-specific context, lycopene has been studied primarily in combination regimens (e.g., with saw palmetto and selenium), where combination data showed benefit, but lycopene's independent contribution cannot be isolated from these studies.
Evidence strength: Epidemiological associations exist. Mechanistic data are promising in vitro and in animal models. Clinical evidence for BPH specifically is indirect and largely from combination trials.
Traditional Use: Zinc-rich foods (oysters, pumpkin seeds, legumes) have been valued in various traditional systems for male reproductive health, though zinc supplementation specifically for prostate enlargement is a more modern nutritional intervention.
Scientific Evidence: The prostate gland is known to accumulate unusually high concentrations of zinc physiologically. Intake of fruits and vegetables, lycopene, and zinc are considered protective factors for benign prostatic hyperplasia (BPH) in observational research. Studies exploring zinc transporter function (including ZIP1 transporters) in prostate tissue have been published in peer-reviewed journals; however, controlled clinical trial evidence specifically on zinc supplementation for prostate size or urinary flow remains limited.
Evidence strength: Epidemiological and mechanistic data suggest an association. Clinical trial evidence for supplementation specifically targeting BPH symptoms or prostate size is insufficient to establish efficacy.
Urtica dioica contains bioactive compounds such as phytosterols (β-sitosterol, daucosterol and associated glucosides) and scopoletin, illustrating how plant sterols appear across multiple botanicals studied for prostate health. Soy isoflavones were found to reduce PSA levels in men with prostate cancer in some studies. Isoflavones may inhibit testosterone-mediated prostate cell growth. Evidence for soy isoflavones in BPH specifically remains preliminary and largely derived from epidemiological observation rather than intervention trials.
Accumulating evidence suggests that other than aging and androgens, modifiable factors such as obesity, diet, dyslipidemia, hormonal imbalance, hypertension, metabolic syndrome, alcohol, and smoking also contribute to the development of BPH, LUTS, or both. Predominantly plant-based diets in some Asian countries have been suggested to account for the low incidence of BPH in those populations.
Some studies have linked increased vegetable intake alone to larger prostate volume, whereas overall healthy dietary patterns — even those including high vegetable consumption — consistently associate with lower BPH risk and reduced disease burden. This distinction highlights that diet may independently affect BPH outcomes, separate from its role in metabolic syndrome.
The evidence regarding dietary fat in BPH is observational. Dietary guidance in evidence-based nutritional references has suggested following a reduced-fat diet that is free from animal products and includes regular consumption of soy foods, based on epidemiological data and plausible hormonal mechanisms, though high-quality interventional evidence is limited.
Greater coffee or total caffeine intake increases the odds of BPH progression, according to evidence summarized in nutritional clinical references. The mechanistic basis likely relates to sympathomimetic and diuretic effects of caffeine on bladder and urethral smooth muscle tone.
Meta-analyses have reported that moderate regular alcohol consumption and physical exercise are inversely associated with BPH and risk for cardiovascular disease, suggesting a possible modest protective association at moderate intake levels. The relationship is U-shaped in some analyses, and heavy alcohol consumption is not considered protective.
Studies suggest that regular physical activity is associated with a lower incidence and reduced progression of BPH. Results from the Health Professionals Follow-Up study show that increasing levels of physical activity were associated with a lower risk of lower urinary tract symptoms independent of weight control. Data from the Massachusetts Male Aging study found a similar inverse association between a man's exercise habits and his odds of clinical BPH.
In a pooled analysis of multiple studies, compared to the sedentary group, the pooled odds ratios for BPH or LUTS were 0.74 for men engaging in moderate physical activity and 0.74 for heavy physical activity. Physical activity reduces the risks of BPH and LUTS. These findings are consistent with other studies demonstrating that the BPH/LUTS complex is associated with modifiable risk factors of cardiovascular disease and suggest that increased physical activity may prevent or attenuate these conditions.
Data from large prospective cohorts also support a role for walking: after controlling for age, race or ethnicity, alcohol consumption, and smoking, physical activity was inversely related to total BPH, surgery for BPH, and symptomatic BPH. Walking, the most prevalent activity, was inversely related to BPH risk; men who walked 2 to 3 hours per week had a 25% lower risk of total BPH.
A meta-analysis demonstrates that a lifestyle with moderate to high-intensity exercise significantly reduces the risk of BPH development.
While the observational and prospective evidence is relatively consistent, a Cochrane review of RCTs found the evidence for physical activity interventions directly reducing LUTS to be of very low quality, and results were uncertain, indicating a need for higher-quality interventional trial data before definitive conclusions can be drawn.
Since physical activity decreases BPH risk, these observations support the development of novel strategies for BPH prevention and treatment targeted toward adiposity, weight loss and lifestyle interventions. Obesity, dyslipidemia, hypertension, and diabetes should be considered risk factors when advising patients with LUTS. Modifications of lifestyle, such as increased physical activity and dietary strategies, may be of benefit for these individuals to improve their LUTS.
Sedentary lifestyle consistently emerges across epidemiological studies as a risk-associated behavior. Lifestyle changes including exercise and diet are important strategies in controlling this common ailment. The mechanisms likely include effects on insulin sensitivity, sex hormone profiles, sympathetic nervous system tone, and systemic inflammation — each of which has been separately linked to prostate size and urinary tract function.
The body of natural-health research on prostate size and urinary flow is characterized by several consistent limitations identified in systematic reviews:
A Cochrane systematic review of 4 randomized, placebo-controlled double-blind trials in 519 men found beta-sitosterol preparations significantly improved IPSS scores (WMD −4.9 points) and peak urinary flow (WMD +3.91 mL/s) versus placebo. A multicentric German RCT (177 men, 6 months, 130 mg/day) confirmed improved IPSS, quality of life, Qmax, and reduced post-void residual. Mechanisms include 5α-reductase inhibition and intraprostatic anti-inflammatory effects. Beta-sitosterol does not consistently reduce prostate volume.
Epidemiological studies link higher dietary boron intake to lower prostate cancer risk and lower PSA levels in men. Boron inhibits aromatase activity, modulates sex hormone metabolism, and has anti-inflammatory effects relevant to prostate size. It is a recognized micronutrient in published BPH prostate supplement formulations alongside beta-sitosterol and zinc, supported by mechanistic, epidemiological, and in vivo evidence.
Campesterol is present in phytosterol blends and saw palmetto extracts that have been evaluated for BPH-related urinary flow improvement in clinical trials. Its 5α-reductase inhibitory activity in vitro supports a mechanistic role. Evidence is primarily based on phytosterol mixture studies, with campesterol as a minor component, rather than campesterol-only trials.
Cucurbita pepo seed preparations show clinical evidence for LUTS improvement in BPH, supported by multiple RCTs and a 2022 meta-analysis confirming improved symptom scores and quality of life over 12 months. Proposed mechanisms include 5α-reductase inhibition via delta-7-sterols, anti-androgen binding, and anti-inflammatory effects. Traditional use for urinary symptoms is documented globally across centuries.
Curcumin inhibits NF-κB and androgen receptor pathways in prostate cells, reducing inflammation and cell proliferation. A pilot RCT using bioavailability-enhanced curcumin with saw palmetto found significantly improved IPSS and Qmax versus placebo after 6 months. A 2019 systematic nutraceutical review confirmed clinical study evidence of curcumin's efficacy on BPH-associated LUTS symptoms.
Phase Ib and Phase IIa randomized double-blind placebo-controlled trials have investigated DIM (as the formulation Infemin) in men with prostatic intraepithelial neoplasia (PIN). An interim analysis in 21 patients showed a 53.3% improvement in maximal urinary flow rate and 45.5% complete PIN regression, though statistical significance was not reached due to small sample size.
A double-blind, placebo-controlled, dose-ranging clinical trial (registered in Cochrane Central) found a G. lucidum extract significantly reduced prostate volume in BPH patients. G. lucidum triterpenoids inhibit 5α-reductase, the enzyme that drives BPH.
Green tea catechins, particularly EGCG, inhibit 5α-reductase, suppress androgen receptor activity, and have anti-inflammatory effects on prostate cells. A clinical study (Ther Adv Urol 2014) found green and black tea extract improved urological health in men with LUTS. A 2019 BPH nutraceutical review lists green tea polyphenols among agents with clinical evidence for BPH/LUTS symptom improvement.
A combination of glycine, L-alanine, and glutamic acid was studied as a treatment for benign prostatic hyperplasia (BPH) symptoms as early as 1958. Clinical studies found the amino acid mixture reduced urinary symptoms and prostate size. L-alanine is one of three amino acids in this historically documented combination.
A pilot RCT (n=40 BPH patients, 15 mg/day for 6 months) found lycopene significantly prevented prostate enlargement on transrectal ultrasonography, reduced PSA, and improved IPSS more than placebo. The PROCOMB multicenter RCT (n=225) found lycopene combined with saw palmetto and selenium improved IPSS and maximum urinary flow beyond single therapies. Lycopene concentrates in prostate tissue and reduces oxidative and inflammatory drivers of prostate growth.
Urtica dioica root is widely used for BPH in Europe with clinical trial support. A large double-blind RCT of 558 men demonstrated significant improvements in IPSS (8-point reduction), post-void residual (−37 mL), and prostate size (−4.8 cc) versus placebo. A 2016 meta-analysis concluded Urtica dioica is an effective and safe treatment for LUTS associated with BPH. Mechanisms include SHBG binding inhibition and prostate anti-inflammatory effects via phytosterols and lignans.
Pentacyclic triterpenoids (ursolic acid, oleanolic acid) are the key active fraction of Pygeum africanum bark, acting synergistically with phytosterols to improve BPH symptoms by inhibiting glucosyl-transferase, reducing prostatic edema, and limiting growth factor-driven fibroblast proliferation. A Cochrane meta-analysis of 18 RCTs (1,562 men) on pygeum extract found nocturia reduced 19%, residual urine 24%, and peak flow increased 23% versus placebo.
Phytosterols (beta-sitosterol) have demonstrated clinical effects on both urinary flow and lower urinary tract symptoms in BPH. Mechanistic studies show inhibition of prostate smooth muscle contraction and suppression of stromal cell growth. Multiple RCTs confirm objective improvements in flow and symptom scores.
Clinical studies including a controlled trial show Pycnogenol reduces urinary symptoms of BPH, including nocturia frequency and urinary intermittency, more effectively than controls. The 2018 PubMed review confirmed BPH urinary symptom reduction. Mechanism may involve anti-inflammatory effects on prostatic tissue.
Plant sterols, specifically beta-sitosterol, have been evaluated in multiple RCTs for BPH-related urinary symptoms. The Cochrane review confirmed improvements in urinary symptom scores and peak flow rate but found no significant reduction in prostate volume. Improvements in peak urinary flow and post-void residual volume are the most consistently demonstrated outcomes.
Pygeum (Prunus africana) bark extract demonstrably improves urinary flow measures and reduces nocturia in men with BPH across 18 RCTs. It increases peak urine flow by approximately 23% and reduces residual urine volume by ~24% versus placebo. The extract does not appear to reduce prostate gland volume itself but relieves functional obstruction through anti-inflammatory and smooth-muscle-relaxing mechanisms.
Pumpkin (Cucurbita pepo) seed oil and extract have clinical evidence for LUTS reduction in BPH. A single-blind RCT versus tamsulosin found significant IPSS improvement with pumpkin seed oil, and the 1-year GRANU placebo-controlled RCT confirmed LUTS improvement. A 2022 meta-analysis of two RCTs confirmed benefits on symptoms and quality of life over 12 months. Mechanisms include 5α-reductase inhibition via delta-7-sterols and anti-inflammatory effects.
A randomized double-blind placebo-controlled trial found quercetin (500 mg twice daily) significantly reduced IPSS in men with CP/CPPS, with 67% achieving >25% improvement versus 20% placebo. Clinical studies have demonstrated efficacy of quercetin on BPH-associated LUTS. Quercetin is a recommended treatment in the UPOINT prostatitis classification system and inhibits androgen receptor signaling and NF-κB–mediated prostate inflammation.
Saw palmetto is one of the most extensively studied herbal remedies for BPH-associated lower urinary tract symptoms (LUTS). Meta-analyses of up to 32 RCTs, involving thousands of men, show mild-to-moderate improvements in symptom scores and peak urinary flow rate. However, a 2012 Cochrane review and a large NCCIH-funded dose-escalation trial found no benefit over placebo at standard or triple doses, leaving efficacy contested. Combination with other agents (lycopene, selenium, tamsulosin) shows more consistent benefit.
Selenium is an essential trace mineral forming selenoproteins that protect prostatic cells from oxidative damage. The PROCOMB multicenter RCT (n=225) found saw palmetto + lycopene + selenium combination improved IPSS and maximum urinary flow beyond single therapies at 12 months. The SPRITE non-inferiority study (n=404) found saw palmetto + selenium + lycopene was non-inferior to tadalafil for LUTS relief. A 2019 BPH nutraceutical review confirmed selenium reduces prostatic inflammation histologically.
The prostate gland accumulates the highest zinc concentration of any soft tissue, and zinc levels are markedly reduced in BPH and prostate cancer tissues. Zinc regulates 5α-reductase activity and promotes apoptosis of prostate epithelial cells. A 2019 BPH nutraceutical review cites zinc as capable of producing similar benefits to lycopene on BPH symptoms; zinc is included in recognized BPH phytotherapy formulations alongside beta-sitosterol and selenium.
Buchu is traditionally used and herbally recommended for benign prostatic hyperplasia (BPH) and associated urinary flow difficulties. Its diuretic, anti-inflammatory, and antimicrobial properties underpin this use. No clinical studies in BPH patients have been published.
Corn silk has a documented traditional use for benign prostatic hyperplasia (BPH) and associated urinary flow difficulties. It is traditionally considered to soothe urinary tract mucosa and reduce prostate inflammation, which may improve urinary flow. No human clinical trials for BPH or urinary flow outcomes have been published.
Flaxseed is listed among alternative therapies used for BPH in authoritative phytotherapy literature reviews, alongside lycopene, zinc, selenium, and rye pollen. Flaxseed lignans (SDG converted by gut bacteria to enterolactone) may modulate estrogen receptor signaling at the prostate, and ALA provides anti-inflammatory effects. Small clinical studies suggest flaxseed lignans may reduce PSA progression and prostate cell proliferation, though large dedicated BPH/urinary flow RCTs are lacking.
Goldenrod is traditionally used for prostatic hypertrophy and associated urinary flow problems, recognized in European and Italian phytotherapy texts. The German Commission E lists enlarged prostate among applications. Its diuretic, anti-inflammatory, and antispasmodic actions are the proposed mechanisms. Formal clinical trials specifically for BPH are lacking.
Horsetail has a traditional use for urinary tract and prostate complaints, documented in multiple herbal traditions. Its diuretic activity—confirmed in a small RCT—may indirectly support urinary flow. Traditional references explicitly list prostate disorders among its historical indications. No clinical trials have evaluated horsetail specifically for benign prostatic hyperplasia.
Hydrangea root is documented in traditional North American folk medicine and TCM as a remedy for enlarged prostate (BPH) and associated urinary flow difficulties. The traditional rationale involves diuretic activity and anti-inflammatory properties. WebMD and RxList both list enlarged prostate as an indication, with no human clinical evidence to support this use.
Traditional medicine in multiple regions uses prickly pear for enlarged prostate symptoms and urological problems. Some clinical reports note subjective improvements in BPH symptoms at 500 mg flower powder three times daily. Controlled trials are absent from peer-reviewed literature.
Go back